Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. 2021 first quarter
The Board of Directors of Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’ today announces that Erik Sundquist is appointed as new CEO after Johan Inborr.
Peptonic Medical AB (publ) (‘Peptonic’ or ‘the Company’) today announces the launch of a in-house developed intimate wash – VagiVital V cleanser – which is
Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Lune Group
Peptonic Medical AB (publ) (‘Peptonic’ or ‘the company’) has announced the appointment of Mikael Svensson, a strategic and operational leader, to the position of General
The Board of Directors of Peptonic Medical AB (the “Company”) hereby announces that the Company’s issue of shares with preferential rights of approximately SEK 25.4
Peptonic Medical AB (publ) (‘Peptonic’ or ‘the company’) announces today that they have signed an agreement with Common Sense, Ltd. (Common Sense) on the distribution
Peptonic Medical AB (publ) org nr 556776-3064(www.aktietorget.se ticker: PMED). Group, Lune Group OY incl subsidiary is included from 2020-06-03 2020 Third quarter (Jul-Sep) Net sales
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) today announced that it has exercised the option to obtain a loan of 7.5 MSEK from Vidarstiftelsen according
Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) announces today that the Company has submitted an application for patent protection for the treatment of genital fungal
Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs about the results of the latest clinical study with VagiVital®. The objective of this study was to
Peptonic Medical (publ) (‘Peptonic’ or ‘Company’) today announced the results of a customer survey that was performed during spring/early summer this year among VagiVital users.
Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Lune Group OY incl subsidiary is included from 2020-06-03. 2020 second quarter (Apr-Jun) Net
Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has received a purchase order from its Chinese partner Shijiazhuang Yuanjia Biotechnology Co. Ltd. (“Yuanjia Bio”) for
The extra ordinary shareholder’s meeting resolved to approve the decision by the Board of Directors to exercise the option to acquire the remaining outstanding shares
In connection with the acquisition of a majority of the shares in Lune Group Oy (“Lune”), Peptonic was granted a call option to acquire the
On 14 May 2020, Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announced that the Company had entered into an agreement to acquire a majority
Peptonic Medical AB (publ) org nr 556776-3064(www.spotlightstockmarket.se ; ticker: PMED) 2020 first quarter (Jan-Mar) Net sales of products KSEK 1,781 (1,477) Gross profit KSEK 985 (802),
Peptonic Medical AB (publ) (’Peptonic’ or ’Company’) today announced that it has filed a patent application for and intimate wash based on the Company’s vaginal
Peptonic Medical AB (publ) (‘Peptonic’ or the ‘Company’) today announced that the Company has filed a patent application concerning the use of its self-care vaginal
The Board of Directors of Peptonic Medical (publ) (“Peptonic” or “The Company”) has decided to postpone the Annual General Meeting (AGM), for the second time,
Peptonic Medical AB (‘Peptonic’ or ’Company’) today announces that its self-care product VagiVital® will be available for purchase in all eighty LloydsApotek’s retail shops in Sweden
The Board of Directors of Peptonic Medical (publ) (“Peptonic” or “The Company”) has decided to postpone the Annual General Meeting (AGM) with a view to
Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com , ticker: PMED). 2019 fourth quarter (Oct-Dec) Net sales of products KSEK 394 (263) Gross profit KSEK 321 (137),
Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has submitted a so called 510k application to the US Food and Drug Adminstration (FDA) to
Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has received a purchase order from its Chinese partner Shijiazhuang Yuanjia Biotechnology Co. Ltd. (“Yuanjia Bio”) for
Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that Kronans Apotek and Apoteksgruppen have decided to carry Peptonic’s self-care product VagiVital® in 170 and 37 of their
Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has closed a private placement transaction with Vidarstiftelsen. The transaction comprised 11 million shares at
Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has entered an agreement with Skyflair Asia concerning the on-line marketing and sale of VagiVital® (‘Product’)
Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has commenced the sale of VagiVital® (‘Product’) in the United Kingdom. From today, the Product can
Peptonic Medical AB (“Peptonic” or “Company”) today announced that that the DQS Medizine GmbH (DQS-MED) certification committee has approved the takeover of the CE mark concerning
In accordance with previously announced plans (e.g. interim report dated August 16th, 2019) Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) today announced that it has
Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has entered an agreement with Shijiazhuang Yuanjia Biotechnology Co. Ltd. (“Yuanjia Bio”) concerning the registration,
Peptonic Medical AB (“Peptonic” or “Company”) today announced that it has entered an agreement with DQS Medizine GmbH (DQS-MED) which means that DQS-MED will become
The last day of trading in the company’s shares PMED including the right to receive subscription rights is May 23, 2019. The first day excluding
2019 first quarter (Jan-Mar) Net sales of products KSEK 1,470 (0) Gross profit KSEK 802 (0), Gross margin 55% (0%) Operating loss KSEK -3,185 (-2,756)
Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) today announced that during May Apoteket AB will expand the distribution of Peptonic’s self-care product VagiVital® from today’s 30
With reference to today’s press release from Spotlight, the trading in PEPTONIC Medical AB’s share PMED will resume today, May 9, 2019 at 09:00. Information
With reference to today’s press release from Spotlight Stock Market a trading halt will take place. Information about the share: Shortname: PMEDISIN-code: SE0005962206Orderbook-ID: 412CCFI: ESVUFRFISN: PEPTONICME/SHOrganization
PEPTONIC medical AB (publ) – today announces that its 2018 Annual Report is available on the Company’s website www.peptonicmedical.se and on the website of Spotlight www.spotlightstockmarket.com. In
Period from January to December 2018 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se, ticker: PMED) 2018 fourth quarter (Oct-Dec) Net sales of products KSEK
Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that the results of a recently conducted survey among women that have used VagiVital® indicate a very strong
Peptonic Medcial AB (publ) (‘Peptonic’ or ‘Company’) today announced that its self-care product for the treatment of vaginal atrophy and dryness – VagiVital® – has
2018 Third quarter (Jul-Sep) Operating loss KSEK -3,420 (-2,969) Loss per share SEK -0.04 (-0.07) First nine months 2018 (Jan-Sep) Operating loss KSEK -9,739 (-8,209)
Stockholm 3rd October 2018 – Peptonic Medical AB (publ) (’Peptonic’) or (’Company’) today announced that it has received a launch order for the Finnish version
Peptonic Medical AB (publ) (’Peptonic’) or (’Company’) today announced that sales of VagiVital® on its webshop has grown faster than expected. The pre-launch phase started
